First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
Read More
Tag: Johnson & Johnson
SMC approve Johnson & Johnson’s systemic light chain amyloidosis therapy
Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the UK
Read More
US approval for J&J and Moderna COVID-19 boosters
EUA amendments ‘based on the available data and information’
Read More
BREAKING NEWS: UK approves J&J’s one-dose COVID-19 vaccine
UK’s Vaccine Taskforce has secured 20 million doses of the vaccine, with initial deliveries expected ‘later this year’
Read More
Janssen seeks EU approval for first CAR-T therapy cilta-cel
Cilta-cel is an investigational CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma
Read More
J&J COVID-19 vaccine hold lifted in the US
Advisory committee voted to resume use of the vaccine under its emergency use authorisation
Read More
EU approval for J&J’s single-shot COVID-19 vaccine
Conditional marketing authorisation closely follows positive opinion from CHMP
Read More
J&J’s COVID-19 vaccine trial paused on safety concerns
Participant in phase III study developed unexplained illness
Read More
J&J to acquire Momenta for $6.5 billion
The move will expand Janssen’s presence in autoimmune diseases
Read More
J&J’s Ebola vaccine wins EU approval
This marks the first major regulatory approval of a vaccine developed by Janssen
Read More
Janssen’s CAR-T shows 100% response rate in multiple myeloma
Longer-term follow-up data from CARTITUDE-1 study show an overall response rate of 100% while 86% experienced a complete response
Read More
Gilead joins GSK, J&J in offering coronavirus vaccine options
The pharma giant is offering its experimental remdesivir in the running for the optimal vaccine candidate.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
